PMID- 23942795
OWN - NLM
STAT- MEDLINE
DCOM- 20140121
LR  - 20231110
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Print)
IS  - 0171-5216 (Linking)
VI  - 139
IP  - 12
DP  - 2013 Dec
TI  - The development of dasatinib as a treatment for chronic myeloid leukemia (CML): 
      from initial studies to application in newly diagnosed patients.
PG  - 1971-84
LID - 10.1007/s00432-013-1488-z [doi]
AB  - PURPOSE: Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI) designed as 
      a prototypic short-acting BCR-ABL-targeted TKI that inhibits BCR-ABL with greater 
      potency compared with imatinib, nilotinib, bosutinib, and ponatinib and has been 
      shown to have potential immunomodulatory effects. Dasatinib is approved for the 
      treatment of all phases of chronic myeloid leukemia (CML) and Philadelphia 
      chromosome-positive acute lymphoblastic leukemia resistant or intolerant to prior 
      imatinib treatment and first-line treatment for CML in chronic phase. In this 
      article, the development of dasatinib as a treatment for patients with CML is 
      reviewed. METHODS: This is a review of the relevant literature regarding 
      dasatinib development in CML (2003-2013). RESULTS: Dasatinib demonstrates 
      efficacy against most BCR-ABL mutations arising during imatinib therapy and is 
      effective in treating patients with imatinib resistance due to other mechanisms. 
      Randomized trial data show that first-line dasatinib provides superior responses 
      compared with imatinib and enables patients to achieve early, deep responses 
      correlated with improved longer-term outcomes. Dasatinib has a generally 
      acceptable safety profile, with most adverse events (AEs) proving manageable and 
      reversible. Cytopenias are commonly observed with dasatinib, and some 
      nonhematologic AEs including pleural effusion have been consistently reported. 
      CONCLUSION: Dasatinib is an effective treatment option for patients with CML.
FAU - Hochhaus, Andreas
AU  - Hochhaus A
AD  - Abteilung Hamatologie/Onkologie, Klinik fur Innere Medizin II, 
      Universitatsklinikum Jena, Erlanger Allee 101, 07740, Jena, Germany, 
      andreas.hochhaus@med.uni-jena.de.
FAU - Kantarjian, Hagop
AU  - Kantarjian H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130813
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (Thiazoles)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
RN  - RBZ1571X5H (Dasatinib)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Dasatinib
MH  - Fusion Proteins, bcr-abl/genetics
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy/genetics
MH  - Mutation
MH  - Neoadjuvant Therapy/methods
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Pyrimidines/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Thiazoles/*therapeutic use
PMC - PMC3825579
EDAT- 2013/08/15 06:00
MHDA- 2014/01/22 06:00
PMCR- 2013/08/13
CRDT- 2013/08/15 06:00
PHST- 2013/07/22 00:00 [received]
PHST- 2013/07/26 00:00 [accepted]
PHST- 2013/08/15 06:00 [entrez]
PHST- 2013/08/15 06:00 [pubmed]
PHST- 2014/01/22 06:00 [medline]
PHST- 2013/08/13 00:00 [pmc-release]
AID - 1488 [pii]
AID - 10.1007/s00432-013-1488-z [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2013 Dec;139(12):1971-84. doi: 
      10.1007/s00432-013-1488-z. Epub 2013 Aug 13.